02.05.2013 • NewsSanofiSanofi R&DDrug Development

Sanofi to Step Up Development of New Diabetes Device

Sanofi is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage of the delayed U.S. launch of competitor Novo Nordisk's new insulin.

The French drugmaker, which on Thursday reported first-quarter results, said it would provide a fresh timeline for the fixed-combination pen device, currently in mid-stage trials, next month.

Having a product that effectively combines two of its key diabetes treatments would bolster Sanofi's portfolio in a market that is becoming increasingly crowded despite the delayed arrival of a new insulin product by Novo Nordisk.

The Danish drugmaker could see the U.S. launch of Tresiba, its biggest drug hope, delayed until 2018 while it conducts more tests to satisfy regulators, it said on Wednesday.

The development of a variable combination of insulin Lantus and Lyxumia faced a setback earlier this year when Sanofi said the product would not start late-stage trials in 2013 because of problems with the injecting device.

The so-called Fix-Flex device was meant to offer a fixed dose of Lyxumia but would let patients adjust their dose of Lantus, which could help them control blood sugar levels better than each therapy used alone.

Lyxumia is part of a new class of diabetes treatments called GLP-1 analogues which prompt the body to release insulin when a diabetic's blood sugar level climbs too high.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read